Malawi Wire

U.N. agencies are calling for an end to food loss and waste as the United Nations marks the International Day of Awareness of Food Loss and Waste Thursday.

A U.N. Environment Program report says over 930 million tons of food waste were generated in 2019. The chief of UNEP’s energy and climate branch, Mark Radka, said that represents about 20% of available food.

“There is evidence that household food waste is generated at a similar per capita level in all countries, regardless of country income level,” he said. “So, households, on average generate about 74 kilograms per person, per year in food waste.”

It has serious implications, given the U.N.’s latest estimates that 828 million people globally are going hungry. Food and Agriculture Organization findings indicate 14% of the world’s food is lost after harvest. An estimated 17% is wasted in retail and at the consumption stage.

FAO Senior Enterprise Development Officer Rosa Rolle calls food loss and waste a global problem that has significant impact on climate, food security, and the sustainability of agri-food systems.

“Over the past two years, agri-food systems across the globe have been disrupted by the COVID-19 pandemic, climate change and the war in Ukraine, pushing millions of people into food insecurity, with hunger and malnutrition on the rise,” she said.

The FAO says food waste and loss accelerate climate change and harm the environment. It says about 31% of total greenhouse gas emissions, which lead to global warming, are attributable to the agri-food system.

The UNEP says reducing food loss and waste could decrease methane emissions by 15% by 2030. It notes methane has more than 80 times the warming power of carbon dioxide over the first 20 years after it reaches the atmosphere. It says at least 25% of today’s global warming by methane is caused by human action.

Source: Voice of America

The James Webb and Hubble telescopes on Thursday revealed their first images of a spacecraft deliberately smashing into an asteroid, as astronomers indicated that the impact looks to have been much greater than expected.

The world’s telescopes turned their gaze toward the space rock Dimorphos earlier this week for a historic test of Earth’s ability to defend itself against a potential life-threatening asteroid in the future.

Astronomers rejoiced as NASA’s Double Asteroid Redirection Test (DART) impactor slammed into its pyramid-sized, rugby ball-shaped target 11 million kilometers (6.8 million miles) from Earth on Monday night.

Images taken by Earth-bound telescopes showed a vast cloud of dust expanding out of Dimorphos — and its big brother Didymos, which it orbits — after the spaceship hit.

While those images showed matter spraying out over thousands of kilometers, the James Webb and Hubble images “zoom in much closer,” said Alan Fitzsimmons, an astronomer at Queen’s University Belfast involved in observations with the ATLAS project.

James Webb and Hubble can offer a view “within just a few kilometers of the asteroids and you can really clearly see how the material is flying out from that explosive impact by DART,” Fitzsimmons told AFP.

“It really is quite spectacular,” he said.An image taken by James Webb’s Near-Infrared Camera (NIRCam) four hours after impact shows “plumes of material appearing as wisps streaming away from the center of where the impact took place,” according to a joint statement from the European Space Agency, James Webb and Hubble.

Hubble images from 22 minutes, five hours and eight hours after impact show the expanding spray of matter from where DART hit.

‘Worried there was nothing left’

Ian Carnelli of the European Space Agency (ESA) said that the “really impressive” Webb and Hubble images were remarkably similar to those taken by the toaster-sized satellite LICIACube, which was just 50 kilometers from the asteroid after separating from the DART spacecraft a few weeks ago.

The images depict an impact that looks “a lot bigger than we expected,” said Carnelli, the manager of the ESA’s Hera mission, which intends to inspect the damage in four years.

“I was really worried there was nothing left of Dimorphos” at first, Carnelli told AFP.

The Hera mission, which is scheduled to launch in October 2024 and arrive at the asteroid in 2026, had expected to survey a crater around 10 meters (33 feet) in diameter.

It now looks like it will be far bigger, Carnelli said, “if there is a crater at all; maybe a piece of Dimorphos was just chunked off.”

The true measure of DART’s success will be exactly how much it diverted the asteroid’s trajectory, so the world can start preparing to defend itself against bigger asteroids that could head our way in the future.

It will likely take Earth-bound telescopes and radars at least a week for a first estimate of how much the asteroid’s orbit has been altered, and three or four weeks before there is a precise measurement, Carnelli said.

‘Huge implications’

“I am expecting a much bigger deflection than we had planned,” he said.

That would have “huge implications in planetary defense because it means that this technique could be used for much larger asteroids,” Carnelli added.

“Until today, we thought that the only deflection technique would be to send a nuclear device.”

Fitzsimmons said that even if no material had been “flung off” Dimorphos, DART still would have slightly affected its orbit.

“But the more material and the faster it’s moving, the more of a deflection there will have been,” he said.

The observations from James Webb and Hubble will help reveal how much — and how quickly — matter sprayed from the asteroid, as well as the nature of its surface.

The asteroid impact marked the first time the two space telescopes observed the same celestial body.

Since launching in December and releasing its first images in July, James Webb has taken the title of most powerful space telescope from Hubble.

Fitzsimmons said the images were “a beautiful demonstration of the extra science you can get by using more than one telescope simultaneously.”

Source: Voice of America

Cyprus released griffon vultures into the wild on Wednesday in the latest attempt to boost a once thriving population now critically endangered by poisoning.

The island’s largest bird of prey has seen its population fall dramatically to the smallest in Europe in recent decades, either from accidental poisoning or changing farming techniques leaving them short of food.

Earlier this year, the population suffered a massive loss from poisoning, reducing numbers to just 8, conservationists say.

They will be joined by eight vultures from Spain, home to Europe’s largest population of griffon vultures, which were released on Wednesday in the mountains north of the coastal city of Limassol. They form a group of 15 brought to the island last year, with seven released in mid-September.

Another 15 are expected from Spain in November. In the past decade, Cyprus had also brought griffon vultures from Crete.

“We were only left with eight birds because of the poison baits placed in the countryside mainly to kill foxes and dogs,” said Melpo Apostolidou, project coodinator at BirdLife Cyprus, one of the partners in the part EU-funded Life with Vultures project.

The birds with names like “Pablo” and “Zenonas” have been fitted with satellite trackers to monitor their movements.

Big, gangly and smelly, griffon vultures play a vital role as nature’s cleanup crew, feeding off dead carcass and reducing the spread of disease. But the use of banned poisons to kill perceived pests which the scavenging bird will then feed on has a knock-on effect.

Nicos Kassinis, a senior officer with Cyprus’s Game and Fauna Service, said authorities were operating several feeding stations and had set up dog units trained to detect poison bait. “It is a serious problem,” he said.

Conservationists say only when the use of poison is effectively addressed can the bird start to thrive again. “Even if we continue to bring vultures from elsewhere, we are just delaying their extinction if we don’t do anything to reduce the frequency of poisoning incidents,” Apostolidou said.

Source: Voice Of America

A renewable energy plant being commissioned in Oregon on Wednesday that combines solar power, wind power and massive batteries to store the energy generated there is the first utility-scale plant of its kind in North America.

The project, which will generate enough electricity to power a small city at maximum output, addresses a key challenge facing the utility industry as the U.S. transitions away from fossil fuels and increasingly turns to solar and wind farms for power. Wind and solar are clean sources of power, but utilities have been forced to fill in gaps when the wind isn’t blowing and the sun isn’t shining with fossil fuels like coal or natural gas.

At the Oregon plant, massive lithium batteries will store up to 120 megawatt-hours of power generated by the 300-megawatt wind farms and 50-megawatt solar farm so it can be released to the electric grid on demand. At maximum output, the facility will produce more than half of the power that was generated by Oregon’s last coal plant, which was demolished earlier this month.

On-site battery storage isn’t new, and interest in solar-plus-battery projects in particular has soared in the U.S. in recent years due to robust tax credits and incentives and the falling price of batteries. The Wheatridge Renewable Energy Facility in Oregon, however, is the first in the U.S. to combine integrated wind, solar and battery storage at such a large scale in one location, giving it even more flexibility to generate continuous output without relying on fossil fuels to fill in the gaps.

The project is “getting closer and closer to having something with a very stable output profile that we traditionally think of being what’s capable with a fuel-based generation power plant,” said Jason Burwen, vice president of energy storage at the American Clean Power Association, an advocacy group for the clean power industry.

“If the solar is chugging along and cloud cover comes over, the battery can kick in and make sure that the output is uninterrupted. As the sun goes down and the wind comes online, the battery can make sure that that’s very smooth so that it doesn’t, to the grid operator, look like anything unusual.”

The plant located in a remote expanse three hours east of Portland is a partnership between NextEra Energy Resources and Portland General Electric, a public utility required to reduce carbon emissions by 100% by 2040 under an Oregon climate law passed last year, one of the most ambitious in the nation.

PGE’s customers are also demanding green power — nearly a quarter-million customers receive only renewable energy — and the Wheatridge project is “key to that decarbonization strategy,” said Kristen Sheeran, PGE’s director of sustainability strategy and resource planning.

Under the partnership, PGE owns one-third of the wind output and purchases all the facility’s power for its renewable energy portfolio. NextEra, which developed the site and operates it, owns two-thirds of the wind output and all of the solar output and storage.

“The mere fact that many other customers are looking at these types of facilities gives you a hint at what we think could be possible,” said David Lawlor, NextEra’s director of business development for the Pacific Northwest. “Definitely customers want firmer generation, starting with the battery storage in the back.”

Large-scale energy storage is critical as the U.S. shifts to more variable power sources like wind and solar, and Americans can expect to see similar projects across the country as that trend accelerates. National Renewable Energy Laboratory models show U.S. storage capacity may rise fivefold by 2050, yet experts say even this won’t be enough to prevent extremely disruptive climate change.

Batteries aren’t the only solution that the clean energy industry is trying out. Pumped storage generates power by sending huge volumes of water downhill through turbines and others are experimenting with forcing water underground and holding it there before releasing it to power turbines.

But interest in batteries for clean energy storage has grown dramatically in recent years at the same time that the cost of batteries is falling and the technology itself is improving, boosting interest in hybrid plants, experts say.

Generating capacity from hybrid plants increased 133% between 2020 and 2021 and by the end of last year, there were nearly 8,000 megawatts of wind or solar generation connected to storage, according to the U.S. Department of Energy’s Lawrence Berkeley National Laboratory, which is managed by the University of California.

The vast majority of such projects are solar power with battery storage, largely because of tax credits, but projects in the pipeline include offshore wind-plus-battery, hydroelectric-plus-battery and at least nine facilities like the one in Oregon that will combine solar, wind and storage. Projects in the pipeline between 2023 and 2025 include ones in Washington, California, Arizona, Idaho, Iowa, Illinois and Oregon, according to Berkeley Lab.

Many researchers and pilots are working on alternatives to lithium ion batteries, however, largely because their intrinsic chemistry limits them to around four hours of storage and a longer duration would be more useful.

“There is no silver bullet. There’s no model or prototype that’s going to meet that entire need … but wind and solar will certainly be in the mix,” said PGE’s Sheeran.

“This model can become a tool for decarbonization across the West as the whole country is driving toward very ambitious climate reduction goals.”

Source: Voice Of America

As Uganda reports more deaths from the latest Ebola outbreak in the country, medical interns at the hospital handling most of the cases have gone on strike. The interns say they are not being provided with adequate personal protective equipment against the deadly virus, which causes a hemorrhagic fever. Uganda’s health ministry has so far confirmed five deaths and 18 probable fatalities out of 36 cases.

Ugandan Health officials say they are holding talks with striking interns at central Mubende district’s hospital, which is handling most of the country’s spreading Ebola outbreak.

President for the Federation for Uganda Medical Interns, Dr. Musa Lumumba, says there is not enough personal protective gear for the interns at the hospital.

Speaking to VOA by phone, he called on Uganda’s Ministry of Health to urgently address the issue to protect doctors-in-training.

“The issue of not having accommodation, so they stay in communities, which communities have got cases of Ebola,” Lumumba said. Protection of those at the frontline. And those at the frontline are the health care workers.”

Uganda Medical Association President, Dr. Samuel Oledo, told VOA one intern, three staff, and a medical student have been confirmed for exposure to the virus and at least three senior health officers (SHO) are showing symptoms.

“We have 34 interns in Mubende. And we have less than 12 doctors employed on the ground,” Oledo said. “If you have interns and they are pulling out at once, it’s catastrophic. And the justifications are clear, honestly. Results have come out today and one of the SHOs who actually performed surgeries with one of the interns on one case has become positive of Ebola.”

Oledo said they suspect as many as 104 medical students in Mubende hospital have been exposed to the virus.

Uganda’s Ministry of Health has yet to confirm the exposures and infections of students and staff at the hospital.

Ministry spokesman Emmanuel Ainebyoona denied there is a lack of protective equipment there to guard against Ebola.

“All the protective gear to safeguard their life is available,” Ainebyoona said. “But like [with] any other infectious disease, fear will be expected. But we are working to ensure that we engage and counsel. And ensure that there are teams to respond.”

Despite the spreading virus, Uganda’s Health Ministry said the situation is under control but acknowledged that three people suspected of being infected with the virus fled Mubende’s isolation unit on Monday.

Officials say security has been beefed up since to avoid a repeat.

Uganda’s Ebola outbreak was first detected last week in Mubende, a central district, but has since spread to neighboring districts Kyegegwa and Kasanda.

Some schools in Kyegegwa have shut down for two weeks to protect students.

First reports of a possible Ebola outbreak came from Kyegegwa’s Kyaka 11 refugee camp, raising alarm bells of a possible quick spread in the packed camp.

But testing ruled out an outbreak in the camp.

After Mubende’s cases were confirmed, the U.N.’s Refugee Agency UNHCR said it added controlled entry measures at refugee settlements.

“We are stepping up some assistance programs that had been curtailed due to lack of funding since July,” said Matthew Crentsil, the UNHCR Uganda representative. “That is procurement of soap. You would agree with me, this is fundamental in curbing the spread of Ebola.”

Uganda has yet to identify the source of the Ebola outbreak, which is the Sudan strain of the virus.

The Sudan strain is less common than the Zaire strain and has no current, effective vaccine.

Uganda’s last Ebola outbreak in 2019 was the Zaire strain. It last reported a Sudan strain outbreak in 2012.

Source: Voice Of America

An experimental Alzheimer’s drug developed by Eisai and Biogen significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said Tuesday.

The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared with a placebo, meeting the study’s main goal and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment.

Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer’s can delay advance of the debilitating disease.

“It’s not a huge effect, but it’s a positive effect,” said Ronald Petersen, director of the Mayo Clinic Alzheimer’s Disease Research Center in Rochester, Minnesota, adding that the results were extremely important for Alzheimer’s research.

“This means that treating amyloid is a step in the right direction,” he said.

Results considered a “win”

Wall Street analysts, such as Salim Syed at Mizuho Securities, have said the results would be considered a “win” if lecanemab slowed the rate of decline by about 25%, and that shares of both companies could jump on the news.

Shares of Biogen and Eisai were halted, but shares of Eli Lilly, which is also developing an Alzheimer’s drug, were up 6.7% in after-hours trading.Lecanemab, like the companies’ previous drug Aduhelm, is an antibody designed to remove those amyloid deposits. Unlike Aduhelm, lecanemab targets forms of amyloid that have not yet clumped together.

The so-called amyloid hypothesis has been challenged by some scientists, particularly after the U.S. Food and Drug Administration’s controversial approval of Aduhelm in 2021 based on its plaque-clearing ability rather than proof that it helped slow cognitive decline. The decision came after the FDA’s own panel of outside experts had advised against approval.

Aduhelm was the first new Alzheimer’s drug approved in 20 years after a long list of high-profile failures for the industry.

Eisai, leader of the 50-50 partnership’s lecanemab program, is seeking FDA approval under the same accelerated pathway as Aduhelm, with a decision expected in early January. But on Tuesday, the Japanese drugmaker said it would use the new efficacy results to submit lecanemab for traditional FDA review.

The company said it will also seek authorization in Japan and Europe during its current fiscal year, ending March 31.

The Phase III trial evaluated the drug’s ability to reduce cognitive and functional decline based on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), a numerical scale used to quantify the severity of dementia in patients in areas such as memory, orientation, judgment and problem-solving and personal care.

Brain swelling

The rate of ARIA-E, a brain swelling side effect associated with anti-amyloid treatments, was 12.5% in the lecanemab group, versus 1.7% in the placebo group.

While the side effect showed up on imaging, many of these cases were not symptomatic, the companies said. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said.

The trial also tracked the rate of micro hemorrhages in the brain, which occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group.

The total incidence of both conditions was 21.3% in the lecanemab group and 9.3% in the placebo group, rates that fell within an expected range, the companies said.

Petersen said the side effect was present, but much less than with Aduhelm, and “certainly tolerable.”

Aduhelm’s approval was a rare bright spot for Alzheimer’s patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

The controversy and reluctance by some payers to cover Aduhelm led Biogen to slash the drug’s price to $28,000 per year from an initial $56,000.

But Medicare, the U.S. government health plan for people 65 and older, this year said it would only pay for Aduhelm if patients were enrolled in a valid clinical trial, which sharply curtailed the medication’s use. Since Alzheimer’s is a disease of aging, an estimated 85% of patients eligible for the drug are covered by the government plan.

The number of Americans living with Alzheimer’s is expected to rise to about 13 million by 2050 from more than 6 million currently, according to the Alzheimer’s Association. Globally, that figure could rise to 139 million by 2050 without an effective treatment, according to Alzheimer’s Disease International.

Source: Voice Of America